Drug intelligence / Profile preview

FamiLact

Development stage: Preclinical
Modality: Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

FamiLact is a synbiotic mouthwash that has been investigated for its efficacy in preventing and treating radiotherapy-induced oral mucositis in oral cancer patients. Clinical trial data indicated that FamiLact significantly reduced the severity and incidence of severe oral mucositis when compared to a normal saline mouthwash. Its therapeutic action is attributed to its synbiotic nature, which involves the modulation of the oral microbiome.

Brand names: FamiLact
Other names: synbiotic mouthwash

Beyond the preview

Go deeper on FamiLact.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FamiLact.

Explore the full profile